Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O75398
UPID:
DEAF1_HUMAN
Alternative names:
Nuclear DEAF-1-related transcriptional regulator; Suppressin; Zinc finger MYND domain-containing protein 5
Alternative UPACC:
O75398; A8K1F8; A8K5R8; C7T5V5; O15152; O75399; O75510; O75511; O75512; O75513; Q9UET1
Background:
Deformed epidermal autoregulatory factor 1 homolog (DEAF-1), also known as Nuclear DEAF-1-related transcriptional regulator, Suppressin, and Zinc finger MYND domain-containing protein 5, plays a pivotal role in transcription regulation. It binds to specific DNA sequences, down-regulating transcription of certain genes, including its own. DEAF-1 is crucial for processes such as neural tube closure, skeletal patterning, and epithelial cell proliferation in the mammary gland. It also influences the expression of peripheral tissue antigens in pancreatic lymph nodes.
Therapeutic significance:
DEAF-1's involvement in Vulto-van Silfout-de Vries syndrome and Neurodevelopmental disorder with hypotonia suggests its potential as a therapeutic target. Understanding DEAF-1's role could open doors to novel treatments for these disorders, emphasizing the importance of further research into its functions and mechanisms.